TY - JOUR T1 - Retrospective evaluation of our cohort of patients with chronic estrinsic allergic alveolitis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA2379 VL - 58 IS - suppl 65 SP - PA2379 AU - Francesco Bini AU - Maria Chiara Papetti AU - Umberto Zanini AU - Bruno Dino Bodini AU - Paola Faverio AU - Adriano Vaghi AU - Giuseppe Pepe AU - Daniele Colombo Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA2379.abstract N2 - Hypersensitivity pneumonitis (HP) is an interstitial lung disease caused by exposure to organic antigens that cause an immune response mediated by T lymphocytes in susceptible subjects. There is an acute/subacute variant and a chronic variant characterized by fibrotic evolution (cHP).We evaluated functional progression in cHP patients, with a monocentric retrospective observational study.We enrolled 66 patients (14 woman) with an average age at diagnosis of 69 years with a median follow up of 56 months.Diagnosis has been made through multidisciplinary evaluation.Hospitalizations for respiratory causes was 1.6 times per patient. Of the 66 patients, 16 died, 4.2 years after diagnosis. FVC % predictedTLC % predictedDLCO % predicted6mWTPAPsBaseline73.47553.933934 6 months73.973.853.03303212 months73.574.144.63213424 months70.269.235.13003636 months59.360.928.32193148 months48.156.319.91593360 months41.050.114.310234Bronchoscopy: on average, BAL at Neutrophils 8.01%, Lymphocytes 22.02%, Macrophages 64.39%, Eosinophils 2.05%, Basophils 0.00%, and a CD4 / CD8 ratio of 1.53. Chest CT scan: the prevalent lesion in patients was honeycombing (59/66), followed by micronodules (45/66), air trapping (44/66) and traction bronchiectasis (34/66).cHP represents a severe disease, with poor prognosis that can worse in the short/medium term from diagnosis.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2379.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -